Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,752 total articles
Energy Transfer looks materially undervalued to me given predictable fee-based cash flow, strategic asset footprint, and optionality from asset sales and deleveraging. I favor a long position sized for medium risk with an entry at $11.50, a stop at $9.50, and a primary target of $14.50 over a 180 trading-day horizon.
Chipotle is trading well below last year's highs on weaker comps and looser sentiment, but the company still generates strong cash flow, high returns on capital, and an aggressive growth plan. The pullback has created a risk/reward setup for a disciplined long over a multi-month horizon.
Marsh & McLennan (MMC) combines high-margin brokerage and consulting franchises, global scale, and exposure to secular growth areas (cyber, climate resilience, human capital) that support mid-to-long-term revenue expansion. Technicals are mixed, but valuation and a modest short-interest backdrop create an opportunity for a disciplined long trade: e…
Cooper-Standard (CPS) is a cyclical auto-parts supplier with improving cash flow and a reasonable valuation (P/E ~16, EV/EBITDA ~6.6). Recent refinancing terms are sub-optimal and increase near-term leverage risk, but the company's free cash flow generation and normalized margins support a tactical long swing. Entry $29.55, target $36.00, stop $26.…
Microsoft ($375.07) is trading well below its 52-week high after a broad tech pullback, but fundamentals and cash generation argue that Azure-led AI adoption will re-rate the stock. This trade idea lays out an actionable long: entry $375.07, stop $350.00, target $450.00 over a long-term horizon (180 trading days).
PLAY has been hammered to a single-digit handle in the past year and now trades at an enterprise value that looks inexpensive versus sales and EBITDA. That creates a tempting contrarian scenario. Still, negative free cash flow, margin pressure and high short interest argue for caution. This trade idea outlines a disciplined entry if management can …
Adyen looks attractively priced relative to its historical trading range and franchise quality. This trade idea lays out an actionable entry at $430.00 with a stop at $380.00 and a two-stage target path to $650.00 and $820.00 depending on catalyst follow-through. Keep the position size disciplined; the opportunity is a mix of mean reversion and val…
Malibu Boats (MBUU) looks like a sensible soft buy at current levels. The recent EUR 150M (USD $175M) acquisition of fast‑growing Saxdor Yachts, consistent product accolades, and a healthy free cash flow profile support upside. Valuation metrics (EV/Sales ~0.59, P/S ~0.6, FCF yield ~6.7%) leave room for a mid‑term rebound into $32, while near‑term …
OPAL Fuels is a capital-intensive RNG operator that recently reported growing revenue but shrinking margins and negative free cash flow. At a market cap of $366.7M and enterprise value near $388M, the stock's fundamentals and technicals favor a tactical short or neutral stance for traders who want defined risk. Entry $2.10, target $1.40, stop $2.50…
Caledonia Mining (CMCL) is a contrarian long with a clear valuation cushion: steady cash generation from the Blanket Mine, a robust Bilboes feasibility study that points to material production growth, a 2.5% dividend, and a sub-$500M market cap. Political and regulatory headlines have compressed the multiple, creating a buying opportunity for patie…
Johnson & Johnson and Protagonist's oral IL-23 receptor antagonist Icotyde won FDA approval on 03/19/2026. The pill creates a realistic shot at taking share from AbbVie's injectable Skyrizi and expands J&J's immunology toolbox. JNJ's fundamentals (market cap $567B, EPS $11.13, FCF $19.3B) and 2.2% dividend make a measured long worthwhile into early…
General Mills (GIS) faces legitimate structural pressure from GLP-1-driven shifts in eating habits and an expanding private-label aisle, which helps explain why the stock trades near 52-week lows and sports an elevated dividend yield. Still, the company is cheap on multiple metrics (P/E ~9, EV/EBITDA ~10), generates meaningful free cash flow, and i…
Rocket Lab (RKLB) remains a bet on small-satellite launch cadence, recurring spacecraft services, and the transition to larger vehicles. The market has punished near-term execution risks and capital raises; this trade targets a tactical rebound off a washout price with defined entry, stop, and targets and a clear timeline for both a swing and a lon…
NextDecade (NEXT) has been re-priced by the market after a supply shock to global LNG and a string of project wins. The company remains pre-revenue but its Rio Grande LNG progress, a strong strategic investor base and a stretched short interest profile create a technical and fundamental setup for a mid-term swing. This is a tactical, higher-risk lo…
We upgrade AMD to a tactical long. The company combines improving AI GPU and datacenter CPU momentum, clean balance sheet and solid free cash flow that make a measured buy here attractive. Technicals and macro sentiment favor a recovery toward prior highs; we lay out entry at $205.00, stop at $185.00 and target at $260.00 for a mid-term swing (45 t…
ProFrac's share move has been linked to the Iran conflict and oil-price spike, but there are durable, domestic drivers that make a tactical long compelling. Tight global crude flows (Strait of Hormuz handling 20% of seaborne oil), a 60% oil price surge, and constrained completion-capacity underpin stronger utilization and pricing for pressure-pumpi…
Exxon Mobil (XOM) is the largest integrated oil company with low leverage, strong free cash flow and advantaged production in the Permian and Guyana. The recent Iran conflict has pushed global crude above $100/bbl, creating a clear upside to Exxon’s near-term earnings and cash generation. We lay out a tactical mid-term long with entry, stop and tar…
ArriVent BioPharma (AVBP) is a clinical-stage oncology name trading at roughly $22.34 with a market cap near $981M. Recent company activity - including AACR preclinical posters and a pivot into a global Phase 3 for firmonertinib - has created a binary investment case. If a short scheduling delay is used to refine endpoints, broaden inclusion criter…
Planet Labs (PL) has gone from a beaten-down name to one of 2025-26's high flyers. With Q4 revenue surprise, bullish guidance and AI/defense catalysts, the stock looks bid — but valuation and momentum leave little margin for error. This note lays out a concrete trade: harvest partial profits now, protect a core position with a trailing stop, and a …
MDA has reported record top-line traction and is visibly pivoting more of its business mix toward defense programs. That combination supports upside through contract awards and backlog conversion over the next 3-9 months. This trade idea is a tactical long looking to capture program wins and margin improvement while keeping a tight stop to limit pr…
H World Group delivered a solid Q4 revenue beat and is rolling out Hanting Inn, a low-capex economy brand that could accelerate unit growth and margins. Against a $15.8B market cap, a modest P/E of 22.5 and a 3.5% dividend yield, the risk/reward favors a long trade toward $58 if management can sustain revenue/margin improvement into 2026. Entry $49…
Huntington (HBAN) trades near $15.45, a valuation that looks inexpensive relative to growth and free cash flow, while near-term catalysts (merger synergies, sector momentum, and dividend yield) could re-rate the stock. The trade below is a mid-term swing (45 trading days) long with a clear stop and target. This is not a blind buy — credit trends an…
10x Genomics (TXG) is an actionable long: the stock trades at a $2.45B market cap, is generating meaningful free cash flow ($130.1M trailing), and is moving toward a higher-margin, consumables-led revenue mix that should compress multiples and re-rate the shares. Technicals are neutral and short interest remains material, so use a defined entry and…
Alpha Tau Medical (DRTS) is a clinical-stage oncology company focused on Alpha DaRT diffusing alpha-emitter radiation therapy. The stock is trading near $7.20 with a market cap of about $634M. 2026 carries multiple catalysts and an expanding radiopharmaceutical market backdrop. This trade idea lays out an actionable long position with precise entry…
This trade idea targets a diversified royalty vehicle whose model emphasizes fixed-dollar royalties instead of percentage-of-revenue or commodity-linked streams. The idea: buy into a de-risked payout profile at an entry of $10.00, use a tight stop at $8.00, and take profits at $14.00 over a mid-term (45 trading days) horizon. Rationale: steady cash…
